Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. Yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for IU-CRLM. This study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in IU-CRLM.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Liver Metastases Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

initially unresectable colorectal liver metastasis (IU-CRLM)
received conversion therapy
underwent conversion hepatectomy

Exclusion criteria

the histologic type of CRLM was not called adenocarcinoma
uncontrollable extrahepatic metastases, such as peritoneal, bone, brain metastasis
history of previous hepatectomy
the primary tumor was not resected or palliative resection
R1 or R2 liver resection

Treatment and study plan

Repeat Liver Surgery

Procedure

repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)

Non-Repeat Liver Surgery

Procedure

Systemic palliative chemotherapy

Primary outcomes

overall survival

Time frame: 5 years

Overall survival after the first resection of liver metastatic lesions

Secondary outcomes

first relapse free survival

Time frame: 5 years

relapse free survival after the first resection of liver metastatic lesions
second relapse free survival

Time frame: 5 years

relapse free survival after the repeat liver surgery of liver metastatic lesions
Severe complication rate after resection of primary and metastatic lesions

Time frame: 30 days after surgery

Grade of III-V complication rate according to Clavien-Dindo

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Important dates

Study start: 2008
Primary completion: 2022
Study completion: 2022
First posted: Jul 18, 2022
Registry last updated: Jul 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed